Safety & regulatory status
BPC-157’s safety story has two very different halves.
A reassuring preclinical package, a near-empty human record, and a hard legal line
BPC-157’s safety story has two very different halves. The preclinical package is genuinely broad: a multi-species toxicology evaluation reported good overall tolerance, though FDA’s own 2026 review of that paper flagged clotting and liver signals and called the toxicology limited in scope and duration. The human half is almost blank, with one phase 1 abstract and no long-term data, so "well tolerated in rats" is being asked to carry far more weight than it can.
Layered on top is a clear regulatory picture. BPC-157 is not FDA-approved, was on the FDA interim 503A category 2 compounding list until the FDA removed it in April 2026 (removal is not approval, and it is still not authorized for compounding), and is prohibited for athletes under WADA S0. An FDA advisory committee recommended it for the authorized bulks list in July 2026, but that recommendation is advice the agency has not acted on. This unit, current as of mid-2026, separates the reassuring parts from the open questions and the legal facts.